Tag: mAbs

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Inches Forward in Development of Myeloid Malignancies

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

Visit website

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myelo...

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

Visit website
Immunotherapy Web Featured Images 81

Use of daratumumab for transplant-ineligible myeloma

During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

Visit website
Immunotherapy Web Featured Images 80

Iodine apamistamab conditioning led to 100% bone marrow transplant rate and engr...

  Dec 29 2020 Tagged AML, mAbs

Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.

Visit website
Immunotherapy Web Featured Images 79

Addition of daratumumab further improves the outcomes for patients with relapsed...

Positive trial results for the anti-CD38 mAb, isatuximab, plus pomalidomide and dexamethasone has led to European approval of this combination, but the regimen requires intravenous administration.

Visit website

Latest updates in myeloma: key takeaways from ASH 2020

Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses recent advances in multiple myeloma research that were presented at ASH 2020.

Visit website